Skip to content

Vibe G Frokjaer

Neurobiology Research Unit, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

3 papers in the library · 30 citations · publishing 2023-2024

Papers

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.

Comprehensive psychoneuroendocrinology February 1, 2023 Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo et al. 24 citations

A single dose of psilocybin did not significantly change peripheral biomarkers of inflammation—high-sensitivity C-reactive protein (hsCRP), tumor-necrosis-factor (TNF), and soluble urokinase plasminogen activator receptor (suPAR)—in 16 healthy individuals one day after administration. All effect sizes were small (Cohen's d ≤ 0.31) and p-values were ≥ 0.23. These findings do not support that a single dose of psilocybin reduces inflammation in healthy people, though future studies should examine additional markers and clinical populations where effects may be more detectable.

Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression

The British Journal of Psychiatry December 5, 2024 Emma S Høgsted, Vincent Beliveau, Brice Ozenne et al. 4 citations

A positive association between serotonin 2A receptor binding in the brain and inward-directed facets of neuroticism—depression, anxiety, self-consciousness, and vulnerability to stress—was confirmed in a new cohort of 80 healthy volunteers using the tracer [11C]Cimbi-36. This association was independent of the cortisol awakening response, an index of hypothalamic-pituitary-adrenal axis function. The findings suggest that interventions targeting the serotonin 2A receptor, such as psilocybin, might be especially effective when tailored to individuals' neuroticism profiles.

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.

Neuroscience applied January 1, 2024 Drummond E-Wen Mcculloch, Juan Pablo Lopez, Christina Dalla et al. 2 citations

Classical psychedelic drugs like psilocybin and LSD stimulate the serotonin 2A receptor and are being investigated for clinical effects in brain disorders. Experts at the ECNP 'New Frontiers meeting' in March 2023 identified key knowledge gaps in psychedelic mechanisms, including the need for appropriate behavioral models, dose optimization, molecular mechanisms, sex differences, and effects on neurotransmitter release and brain activity. The meeting highlighted the importance of preclinical and neuroimaging research to address these gaps.